Waitzberg, Dan Linetzky 
; Guarner, Francisco; Hojsak, Iva; Ianiro, Gianluca; Polk, D. Brent; Sokol, Harry
Source: Advances in therapy. Unidade: FM
Subjects: ANTIBIÓTICOS, DIARREIA, BIOTA INTESTINAL, PROBIÓTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WAITZBERG, Dan Linetzky et al. Can the evidence-based use of probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) mitigate the clinical effects of antibiotic-associated dysbiosis?. Advances in therapy, v. 41, n. 3, p. 901-914, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/76934. Acesso em: 25 jan. 2026.APA
Waitzberg, D. L., Guarner, F., Hojsak, I., Ianiro, G., Polk, D. B., & Sokol, H. (2024). Can the evidence-based use of probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) mitigate the clinical effects of antibiotic-associated dysbiosis? Advances in therapy, 41( 3), 901-914. doi:10.1007/s12325-024-02783-3NLM
Waitzberg DL, Guarner F, Hojsak I, Ianiro G, Polk DB, Sokol H. Can the evidence-based use of probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) mitigate the clinical effects of antibiotic-associated dysbiosis? [Internet]. Advances in therapy. 2024 ; 41( 3): 901-914.[citado 2026 jan. 25 ] Available from: https://observatorio.fm.usp.br/handle/OPI/76934Vancouver
Waitzberg DL, Guarner F, Hojsak I, Ianiro G, Polk DB, Sokol H. Can the evidence-based use of probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) mitigate the clinical effects of antibiotic-associated dysbiosis? [Internet]. Advances in therapy. 2024 ; 41( 3): 901-914.[citado 2026 jan. 25 ] Available from: https://observatorio.fm.usp.br/handle/OPI/76934
